Invivyd (NASDAQ:IVVD – Get Rating) had its target price decreased by Morgan Stanley from $3.00 to $2.00 in a research note published on Tuesday, Benzinga reports. Morgan Stanley currently has an underweight rating on the stock.

Invivyd Price Performance

Shares of IVVD opened at $2.20 on Tuesday. The stock's fifty day moving average price is $1.97. Invivyd has a 12-month low of $1.42 and a 12-month high of $12.11. The company has a market capitalization of $239.76 million, a PE ratio of -0.85 and a beta of -0.50.

Invivyd (NASDAQ:IVVD – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.04. Sell-side analysts predict that Invivyd will post -2.18 EPS for the current year.

About Invivyd

Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.

See Also

• Get a free copy of the StockNews.com research report on Invivyd (IVVD)
• 3 Retail Stocks Ringing the Register in 2023
• When Will Crane Holdings Take Flight?
• Is It Time To Get Aggressive With Defense Stocks?
• EVgo Stock is Charged Up to Ride the EV Adoption Wave
• Qualcomm Gets a Boost from Analysts, but is it Time to Buy?

Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.